The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Mitochondrial Cholesterol Contributes to Chemotherapy Resistance in Hepatocellular Carcinoma
Abstract
Cholesterol metabolism is deregulated in carcinogenesis, and cancer cells exhibit enhanced mitochondrial cholesterol content whose role in cell death susceptibility and cancer therapy has not been investigated. Here, we describe that mitochondria from rat or human hepatocellular carcinoma (HC) cells (HCC) or primary tumors from patients with HC exhibit increased mitochondrial cholesterol levels. HCC sensitivity to chemotherapy acting via mitochondria is enhanced upon cholesterol depletion by inhibition of hydroxymethylglutaryl-CoA reductase or squalene synthase (SS), which catalyzes the first committed step in cholesterol biosynthesis. HCC transfection with siRNA targeting the steroidogenic acute regulatory protein StAR, a mitochondrial cholesterol–transporting polypeptide which is overexpressed in HCC compared with rat and human liver, sensitized HCC to chemotherapy. Isolated mitochondria from HCC with increased cholesterol levels were resistant to mitochondrial membrane permeabilization and release of cytochrome c or Smac/DIABLO in response to various stimuli including active Bax. Similar behavior was observed in cholesterol-enriched mitochondria or liposomes and reversed by restoring mitochondrial membrane order or cholesterol extraction. Moreover, atorvastatin or the SS inhibitor YM-53601 potentiated doxorubicin-mediated HCC growth arrest and cell death in vivo. Thus, mitochondrial cholesterol contributes to chemotherapy resistance by increasing membrane order, emerging as a novel therapeutic niche in cancer therapy. [Cancer Res 2008;68(13):5246–56]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Role of cholesterol and lipid organization in disease
Maxfield, F. R., & Tabas, I. (2005) · Nature · doi:10.1038/nature04399 · Cited by 1,293
The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore
Kokoszka, J. E., Waymire, K. G., Levy, S. E., Sligh, J. E., Cai, J., Jones, D. P., MacGregor, G. R., & Wallace, D. C. (2004) · Nature · doi:10.1038/nature02229 · Cited by 1,086
Jones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067
Cholesterol, lipid rafts, and disease
Simons, K., & Ehehalt, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16390 · Cited by 989
Cholesterol, lipid rafts, and disease
Simons, K., & Ehehalt, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216390 · Cited by 916
Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E., & Lippman, S. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1751 · Cited by 819
The mitochondrial transporter family (SLC25): physiological and pathological implications
Palmieri, F. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1099-7 · Cited by 756
Cited by
The Role of Cholesterol in Cancer
Kuzu, O. F., Noory, M. A., & Robertson, G. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2613 · Cited by 708
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Ribas, V., GarcÃa-Ruiz, C., & Fernández-Checa, J. C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00151 · Cited by 571
Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421601112 · Cited by 454
Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH
Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.016 · Cited by 368
Self-citation
Metadata
- Authors
- Montero, J., Morales, A., Llacuna, L., Lluis, J. M., Terrones, O., Basañez, G., Antonsson, B., Prieto, J., García-Ruiz, C., Colell, A., & Fernández-Checa, J. C.
- Venue
- Cancer Research
- Published
- 2008-07-01
- Volume
- 68
- Issue
- 13
- Pages
- 5246-5256
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2165855078
- Cited by
- 276
- References
- 49
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mitochondrial Cholesterol Contributes to Chemotherapy Resistance in Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-07-6161
- The paper
- Montero, J., Morales, A., Llacuna, L., Lluis, J. M., Terrones, O., Basañez, G., Antonsson, B., Prieto, J., García-Ruiz, C., Colell, A., & Fernández-Checa, J. C. (2008). Mitochondrial Cholesterol Contributes to Chemotherapy Resistance in Hepatocellular Carcinoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-07-6161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.